NEW YORK (Reuters) - AVI BioPharma Inc's shares could get a boost if its drug targeting treatment for a rare fatal form of muscular dystrophy proves to be effective in clinical drug trials, according to an article in the April 2 edition of Barron's. Clinical trial results for AVI's drug Eteplirsen were expected later this month, Barron's said. The drug is designed to treat Duchenne muscular dystrophy, a disease that develops in early childhood and most often results in the death by age 30
More here:
Drug for rare disease may lift AVI BioPharma shares: Barron's
Related External LinksWatch
No comments:
Post a Comment